Pharma BD Deal Intelligence
Closing transferred Eklira, Duaklir Genuair, and abediterol to AstraZeneca for $875M upfront and up to $1.22B in milestones, giving AZ immediate on-market COPD…
Analysts framed the deal as core to AstraZeneca's standalone strategy after rebuffing Pfizer, accelerating the respiratory franchise's contribution to…
AstraZeneca later transferred global rights for Eklira and Duaklir to Covis Pharma, indicating the acquired assets ultimately did not meet long-term portfolio…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca agreed to acquire Almirall's respiratory business including Eklira/Tudorza and the Genuair device for $875M upfront plus up to $1.22B in development/launch/sales milestones. Strengthened AstraZeneca's COPD/asthma portfolio alongside Symbicort and Pulmicort; closed November 3, 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Almirall S.A. (respiratory franchise) (this deal) | 2014 | $2.1B | 32 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2014 deals · AstraZeneca PLC deals · Respiratory deals